Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2012

Jensen Donald M, Pol Stanislas

Abstract excerpt

An association between variations at the IL28B gene locus and HCV clearance (spontaneous recovery or sustained virological response under pegylated interferon (PEG-IFN) and ribavirin (RBV) has been extensively described. In genotype 1-infected patients, the new direct antiviral agents (DAA) including the two approved protease inhibitors boceprevir and telaprevir, in association with the PEG-IFN/RBV combination is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Patient Selection

Share to Serine Proteinase Inhibitors

Source

Identifiers

PMID: 22212576
DOI: 10.1111/j.1478-3231.2011.02712.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?PMID 22212576Read ↗

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Semantic proximity Read ↗

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?Semantic proximity Read ↗

IL28B in the era of direct-acting antivirals for hepatitis C.Semantic proximity Read ↗

IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?Semantic proximity Read ↗

Hepatitis C pharmacogenetics: State of the art in 2010Semantic proximity Read ↗

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?Semantic proximity Read ↗

IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Semantic proximity Read ↗

IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.Semantic proximity Read ↗

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.Semantic proximity Read ↗

Effect of IL28B genotype on hepatitis B and C virus infection.Semantic proximity Read ↗

Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Semantic proximity Read ↗

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.